NCT06709040View on ClinicalTrials.gov

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Enrolling by invitationOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

April 14, 2034

Study Completion Date

April 14, 2034

Conditions

Growth Hormone DeficiencyNeoplasmsDiabetes Mellitus Type 2

Interventions

DRUG

Somapacitan

Participants will be treated with commercially available somapacitan according to routine clinical practice at the discretion of the treating physician.

Trial Locations (1)

Unknown

University of Glasgow, Glasgow